BR112019024300A2 - Ativadores de guanilato ciclase solúvel com modo duplo de ação e inibidores da fosfodiesterase e usos dos mesmos - Google Patents

Ativadores de guanilato ciclase solúvel com modo duplo de ação e inibidores da fosfodiesterase e usos dos mesmos Download PDF

Info

Publication number
BR112019024300A2
BR112019024300A2 BR112019024300-3A BR112019024300A BR112019024300A2 BR 112019024300 A2 BR112019024300 A2 BR 112019024300A2 BR 112019024300 A BR112019024300 A BR 112019024300A BR 112019024300 A2 BR112019024300 A2 BR 112019024300A2
Authority
BR
Brazil
Prior art keywords
guanilate
activators
action
same
dual mode
Prior art date
Application number
BR112019024300-3A
Other languages
English (en)
Inventor
Naef Reto
Tenor Hermann
Original Assignee
Topadur Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Topadur Pharma Ag filed Critical Topadur Pharma Ag
Publication of BR112019024300A2 publication Critical patent/BR112019024300A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

a presente invenção refere-se a compostos de fórmula i ou um sal, solvato ou hidrato farmaceuticamente aceitável do mesmo e seu uso em métodos de tratamento ou prevenção de uma doença aliviada pela inibição de pde5 em um mamífero humano ou não humano. i
BR112019024300-3A 2017-05-22 2018-05-22 Ativadores de guanilato ciclase solúvel com modo duplo de ação e inibidores da fosfodiesterase e usos dos mesmos BR112019024300A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17172193 2017-05-22
EP17172193.9 2017-05-22
PCT/EP2018/063339 WO2018215433A1 (en) 2017-05-22 2018-05-22 Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
BR112019024300A2 true BR112019024300A2 (pt) 2020-06-16

Family

ID=58772403

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019024300-3A BR112019024300A2 (pt) 2017-05-22 2018-05-22 Ativadores de guanilato ciclase solúvel com modo duplo de ação e inibidores da fosfodiesterase e usos dos mesmos

Country Status (14)

Country Link
US (2) US11155558B2 (pt)
EP (1) EP3630769A1 (pt)
JP (1) JP7182568B2 (pt)
KR (1) KR20200010228A (pt)
CN (1) CN110621676B (pt)
AU (1) AU2018274599B9 (pt)
BR (1) BR112019024300A2 (pt)
CA (1) CA3060525A1 (pt)
IL (1) IL269835B (pt)
MX (1) MX2019013626A (pt)
PH (1) PH12019550217A1 (pt)
RU (1) RU2758373C2 (pt)
WO (1) WO2018215433A1 (pt)
ZA (1) ZA201908389B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3887376A1 (en) * 2018-11-28 2021-10-06 Topadur Pharma AG Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
CA3166602A1 (en) 2020-02-05 2021-08-12 Nicoletta Almirante Compositions for the treatment of glaucoma and ocular hypertension
WO2021245192A1 (en) 2020-06-04 2021-12-09 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
KR20220009806A (ko) * 2020-07-16 2022-01-25 제이투에이치바이오텍 (주) 이중 억제제 화합물 및 이들의 의약 용도
EP4236952A1 (en) 2020-11-02 2023-09-06 Nicox S.A. No-pde5 inhibitor for use in treating dry age-related macular degeneration, geographic atrophy and glaucoma-associated neurodegeneration
WO2023166013A1 (en) 2022-03-02 2023-09-07 Topadur Pharma Ag Topical compositions and uses therof
KR20230129639A (ko) 2022-03-02 2023-09-11 연세대학교 산학협력단 이중작용 pde5 억제제/질산유기에스터의 국소 혈류 증진을 위한 경피 투약 형태

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958926A (en) 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB2346877B (en) 1997-11-12 2001-12-05 Bayer Ag 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
CA2312900A1 (en) 1997-12-02 1999-06-10 Powderject Vaccines, Inc. Transdermal delivery of particulate vaccine compositions
GB9823103D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
KR100358083B1 (ko) * 2000-02-17 2002-10-25 에스케이케미칼주식회사 피롤로피리미디논 유도체와 이의 제조방법, 그리고 이의용도
WO2001096334A2 (en) 2000-06-15 2001-12-20 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists
US6831074B2 (en) * 2001-03-16 2004-12-14 Pfizer Inc Pharmaceutically active compounds
FR2842809A1 (fr) 2002-07-26 2004-01-30 Greenpharma Sas NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
US20020182162A1 (en) 2002-08-07 2002-12-05 Mohsen Shahinpoor Nitric oxide (NO) donor+cGMP-PDE5 inhibitor as a topical drug for enhanced hair growth
CN100374441C (zh) * 2003-06-06 2008-03-12 天津倍方科技发展有限公司 二氢吡咯[2，3-d]嘧啶-4-酮衍生物，其制备方法及其制药用途
WO2005026145A2 (en) 2003-09-12 2005-03-24 Warner-Lambert Company Llc Quinolone antibacterial agents
TW200621257A (en) 2004-10-20 2006-07-01 Astellas Pharma Inc Pyrimidine derivative fused with nonaromatic ring
CN1966506A (zh) 2005-11-17 2007-05-23 上海特化医药科技有限公司 吡唑并嘧啶酮衍生物及其制备方法和用途
AU2006341342B2 (en) 2006-04-04 2010-05-20 Dong-A Pharmaceutical.Co., Ltd. Agent for the prevention and treatment of prostatic hyperplasia comprising pyrazolopyrimidinone compound
BRPI1006869A2 (pt) 2009-01-17 2016-03-15 Bayer Schering Pharma Ag estimuladores de sgc ou ativadores da sgc em combinação com inibidores da pde5 para o tratamento de disfunção erétil
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
EP2512479B1 (en) 2009-12-18 2016-03-30 Exodos Life Sciences Limited Partnership Compositions for treating peripheral vascular disease
CN102134242B (zh) * 2011-01-21 2013-08-28 浙江大德药业集团有限公司 一种用于治疗阳痿的快速长效的化合物

Also Published As

Publication number Publication date
RU2758373C2 (ru) 2021-10-28
PH12019550217A1 (en) 2020-09-14
RU2019133200A3 (pt) 2021-06-23
MX2019013626A (es) 2020-01-13
JP7182568B2 (ja) 2022-12-02
ZA201908389B (en) 2020-11-25
US11155558B2 (en) 2021-10-26
CA3060525A1 (en) 2018-11-29
WO2018215433A1 (en) 2018-11-29
AU2018274599B9 (en) 2022-04-07
EP3630769A1 (en) 2020-04-08
IL269835B (en) 2022-08-01
US11905293B2 (en) 2024-02-20
RU2019133200A (ru) 2021-06-23
JP2020520945A (ja) 2020-07-16
US20200181149A1 (en) 2020-06-11
AU2018274599A1 (en) 2019-11-14
CN110621676A (zh) 2019-12-27
KR20200010228A (ko) 2020-01-30
US20220073529A1 (en) 2022-03-10
IL269835A (en) 2019-11-28
AU2018274599B2 (en) 2022-03-03
CN110621676B (zh) 2024-02-09

Similar Documents

Publication Publication Date Title
BR112019024300A2 (pt) Ativadores de guanilato ciclase solúvel com modo duplo de ação e inibidores da fosfodiesterase e usos dos mesmos
BR112019007143A2 (pt) compostos de pirazolo[1,5-a]piridina substituídos como inibidores da ret cinase
CY1122986T1 (el) Παραγωγα 1,2,4-οξαδιαζολιου ως ανοσοτροποποιητες
PH12020500485A1 (en) Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
BR112019002576A2 (pt) composto, medicamento¸ métodos para inibição de gcn2 em um mamífero e para a profilaxia ou tratamento de câncer em um mamífero, e, uso do composto ou um sal do mesmo
SV2018005655A (es) "derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cancer"
MX360634B (es) Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos.
BR112015012693A2 (pt) derivados de pirimidona e seu uso no tratamento, melhora ou prevenção de uma doença viral
EA201690752A1 (ru) Ингибиторы g12c kras
BR112015022431A2 (pt) derivados de 3-(aril ou heteroaril) metilenoindolin-2-ona como inibidores de quinases da via de sinalização de células-tronco cancerosas para o tratamento de câncer
BR112021019643A2 (pt) Compostos de pirazolopiridina como inibidores do ret e uso dos mesmos
PH12016502353A1 (en) Pharmaceutical composition
EA201790088A1 (ru) Ингибиторы syk
PH12018500957A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
ME00936B (me) Postupci liječenja kancera upotrebom piridopirimidinonskih inhibitora pi3k alfa
MX363950B (es) Derivados de urea utiles como inhibidores de quinasa.
BR112016027041A8 (pt) combinações farmacêuticas para tratamento do câncer
BR112018016554A2 (pt) composto de uréia, método de preparação deste e uso médico deste
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
MX2017009600A (es) Derivados de 2-fenil-3h-imidazo[4,5-b]piridina utiles como inhibidores de actividad de receptor huerfano similar a tirosina cinasa (ror1) de tirosina cinasa de mamifero.
MX2015012896A (es) Inhibidores de pirrolo [2,3-b] piridina cdk9 cinasa.
MX2018008307A (es) Derivado de ascoclorina y uso del mismo como activador de proteina cinasa activada por adenosin monofosfato (ampk).
EA201790179A1 (ru) [1,2,4]триазоло[4,3-b]пиридазины для применения в лечении пролиферативных заболеваний
AR099766A1 (es) Inhibidores de la quinasa asociada al adaptador 1, composiciones que los comprenden y métodos para utilizarlos

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]